While expression of PD-L1 in the tumor, microsatellite instability (MSI) and TMB are used as predictive biomarkers of response to anti-PD-1 agents for various cancers, none have been shown to be clinically relevant for MCC (37). Here, PDCD1 is linked to neoplasm.